APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Group ACYW135 Meningococcal Polysaccharide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026

Report ID 173996380430 December 2025195 pages

Choose your research edition.

Industry ResearchGroup ACYW135 Meningococcal Polysaccharide Vaccine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Group ACYW135 Meningococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Group ACYW135 Meningococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Group ACYW135 Meningococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Group ACYW135 Meningococcal Polysaccharide Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Group ACYW135 Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Group ACYW135 Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Group ACYW135 Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Group ACYW135 Meningococcal Polysaccharide Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Group ACYW135 Meningococcal Polysaccharide Vaccine market include Zhejiang Tianyuan Biopharmaceutical Co., Ltd, Yuxi Watson Biotechnology Co., Ltd, CanSino Biologics AG, Hualan Biovaccine Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd, Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd, Beijing Institute of Biological Products Co., Ltd, Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd and Walvax Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Group ACYW135 Meningococcal Polysaccharide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Group ACYW135 Meningococcal Polysaccharide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Group ACYW135 Meningococcal Polysaccharide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Group ACYW135 Meningococcal Polysaccharide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Group ACYW135 Meningococcal Polysaccharide Vaccine Segment by Company

Zhejiang Tianyuan Biopharmaceutical Co., Ltd

Yuxi Watson Biotechnology Co., Ltd

CanSino Biologics AG

Hualan Biovaccine Co., Ltd

Chengdu Kanghua Biological Products Co., Ltd

Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd

Beijing Institute of Biological Products Co., Ltd

Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd

Walvax Biotechnology

Sanofi-Pasteur

Group ACYW135 Meningococcal Polysaccharide Vaccine Segment by Type

Class I Vaccines

Class II Vaccines

Group ACYW135 Meningococcal Polysaccharide Vaccine Segment by Application

Hospital

Clinic

Group ACYW135 Meningococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Group ACYW135 Meningococcal Polysaccharide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Group ACYW135 Meningococcal Polysaccharide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Group ACYW135 Meningococcal Polysaccharide Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Group ACYW135 Meningococcal Polysaccharide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Group ACYW135 Meningococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Group ACYW135 Meningococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Group ACYW135 Meningococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Group ACYW135 Meningococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Group ACYW135 Meningococcal Polysaccharide Vaccine industry.

Chapter 3: Detailed analysis of Group ACYW135 Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Group ACYW135 Meningococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Group ACYW135 Meningococcal Polysaccharide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Trends Table 2. Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Drivers Table 3. Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges Table 4. Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Restraints Table 5. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Share by Company (2021-2026) Table 7. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company, Product Type & Application Table 13. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Group ACYW135 Meningococcal Polysaccharide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Class I Vaccines Table 18. Significant Companies of Class II Vaccines Table 19. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Company Information Table 64. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Business Overview Table 65. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 67. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Recent Development Table 68. Yuxi Watson Biotechnology Co., Ltd Company Information Table 69. Yuxi Watson Biotechnology Co., Ltd Business Overview Table 70. Yuxi Watson Biotechnology Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Yuxi Watson Biotechnology Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 72. Yuxi Watson Biotechnology Co., Ltd Recent Development Table 73. CanSino Biologics AG Company Information Table 74. CanSino Biologics AG Business Overview Table 75. CanSino Biologics AG Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. CanSino Biologics AG Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 77. CanSino Biologics AG Recent Development Table 78. Hualan Biovaccine Co., Ltd Company Information Table 79. Hualan Biovaccine Co., Ltd Business Overview Table 80. Hualan Biovaccine Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hualan Biovaccine Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 82. Hualan Biovaccine Co., Ltd Recent Development Table 83. Chengdu Kanghua Biological Products Co., Ltd Company Information Table 84. Chengdu Kanghua Biological Products Co., Ltd Business Overview Table 85. Chengdu Kanghua Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Chengdu Kanghua Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 87. Chengdu Kanghua Biological Products Co., Ltd Recent Development Table 88. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Company Information Table 89. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Business Overview Table 90. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 92. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Recent Development Table 93. Beijing Institute of Biological Products Co., Ltd Company Information Table 94. Beijing Institute of Biological Products Co., Ltd Business Overview Table 95. Beijing Institute of Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Beijing Institute of Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 97. Beijing Institute of Biological Products Co., Ltd Recent Development Table 98. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Company Information Table 99. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Business Overview Table 100. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 102. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Recent Development Table 103. Walvax Biotechnology Company Information Table 104. Walvax Biotechnology Business Overview Table 105. Walvax Biotechnology Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Walvax Biotechnology Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 107. Walvax Biotechnology Recent Development Table 108. Sanofi-Pasteur Company Information Table 109. Sanofi-Pasteur Business Overview Table 110. Sanofi-Pasteur Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sanofi-Pasteur Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 112. Sanofi-Pasteur Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Group ACYW135 Meningococcal Polysaccharide Vaccine Distributors List Table 116. Group ACYW135 Meningococcal Polysaccharide Vaccine Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Group ACYW135 Meningococcal Polysaccharide Vaccine Product Image Figure 2. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Class I Vaccines Image Figure 10. Class II Vaccines Image Figure 11. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Group ACYW135 Meningococcal Polysaccharide Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Class I Vaccines
  • Class II Vaccines
Applications
  • Hospital
  • Clinic
Companies covered
  • Zhejiang Tianyuan Biopharmaceutical Co., Ltd
  • Yuxi Watson Biotechnology Co., Ltd
  • CanSino Biologics AG
  • Hualan Biovaccine Co., Ltd
  • Chengdu Kanghua Biological Products Co., Ltd
  • Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd
  • Beijing Institute of Biological Products Co., Ltd
  • Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd
  • Walvax Biotechnology
  • Sanofi-Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Group ACYW135 Meningococcal Polysaccharide Vaccine Market Dynamics
  1. 2.1 Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Trends
  2. 2.2 Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Drivers
  3. 2.3 Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Restraints
3 Group ACYW135 Meningococcal Polysaccharide Vaccine Market by Company
  1. 3.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company Product Type and Application
  8. 3.8 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Group ACYW135 Meningococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Group ACYW135 Meningococcal Polysaccharide Vaccine Market by Type
  1. 4.1 Group ACYW135 Meningococcal Polysaccharide Vaccine Type Introduction
  2. 4.1.1 Class I Vaccines
  3. 4.1.2 Class II Vaccines
  4. 4.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Type
  5. 4.2.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Type
  9. 4.3.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032)
5 Group ACYW135 Meningococcal Polysaccharide Vaccine Market by Application
  1. 5.1 Group ACYW135 Meningococcal Polysaccharide Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Application
  5. 5.2.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Application
  9. 5.3.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032)
6 Group ACYW135 Meningococcal Polysaccharide Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
7 Group ACYW135 Meningococcal Polysaccharide Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd
  2. 8.1.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Company Information
  3. 8.1.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Business Overview
  4. 8.1.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  6. 8.1.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Recent Developments
  7. 8.2 Yuxi Watson Biotechnology Co., Ltd
  8. 8.2.1 Yuxi Watson Biotechnology Co., Ltd Company Information
  9. 8.2.2 Yuxi Watson Biotechnology Co., Ltd Business Overview
  10. 8.2.3 Yuxi Watson Biotechnology Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Yuxi Watson Biotechnology Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  12. 8.2.5 Yuxi Watson Biotechnology Co., Ltd Recent Developments
  13. 8.3 CanSino Biologics AG
  14. 8.3.1 CanSino Biologics AG Company Information
  15. 8.3.2 CanSino Biologics AG Business Overview
  16. 8.3.3 CanSino Biologics AG Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CanSino Biologics AG Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  18. 8.3.5 CanSino Biologics AG Recent Developments
  19. 8.4 Hualan Biovaccine Co., Ltd
  20. 8.4.1 Hualan Biovaccine Co., Ltd Company Information
  21. 8.4.2 Hualan Biovaccine Co., Ltd Business Overview
  22. 8.4.3 Hualan Biovaccine Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hualan Biovaccine Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  24. 8.4.5 Hualan Biovaccine Co., Ltd Recent Developments
  25. 8.5 Chengdu Kanghua Biological Products Co., Ltd
  26. 8.5.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
  27. 8.5.2 Chengdu Kanghua Biological Products Co., Ltd Business Overview
  28. 8.5.3 Chengdu Kanghua Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Chengdu Kanghua Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  30. 8.5.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments
  31. 8.6 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd
  32. 8.6.1 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Company Information
  33. 8.6.2 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Business Overview
  34. 8.6.3 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  36. 8.6.5 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Recent Developments
  37. 8.7 Beijing Institute of Biological Products Co., Ltd
  38. 8.7.1 Beijing Institute of Biological Products Co., Ltd Company Information
  39. 8.7.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  40. 8.7.3 Beijing Institute of Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Beijing Institute of Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  42. 8.7.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  43. 8.8 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd
  44. 8.8.1 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Company Information
  45. 8.8.2 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Business Overview
  46. 8.8.3 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  48. 8.8.5 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Recent Developments
  49. 8.9 Walvax Biotechnology
  50. 8.9.1 Walvax Biotechnology Company Information
  51. 8.9.2 Walvax Biotechnology Business Overview
  52. 8.9.3 Walvax Biotechnology Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Walvax Biotechnology Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  54. 8.9.5 Walvax Biotechnology Recent Developments
  55. 8.10 Sanofi-Pasteur
  56. 8.10.1 Sanofi-Pasteur Company Information
  57. 8.10.2 Sanofi-Pasteur Business Overview
  58. 8.10.3 Sanofi-Pasteur Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi-Pasteur Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  60. 8.10.5 Sanofi-Pasteur Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Group ACYW135 Meningococcal Polysaccharide Vaccine Value Chain Analysis
  2. 9.1.1 Group ACYW135 Meningococcal Polysaccharide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Mode & Process
  6. 9.2 Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Group ACYW135 Meningococcal Polysaccharide Vaccine Distributors
  9. 9.2.3 Group ACYW135 Meningococcal Polysaccharide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst